RSS
Location:HOMECSOMS > CJOMS > Papers > Clinical observation of dexmedetomidine on sedation and analgesia in patients af

Clinical observation of dexmedetomidine on sedation and analgesia in patients af

2013-07-26 15:22:56 Source: Author:JIANG Chao, CHEN Zhi-feng, JIANG Hong Hits:0
[Abstract] PURPOSE: To investigate sedation,analgesic effect of dexmedetomidine given to oral and maxillofacial tumor postoperative patients with tracheostomy tube. METHODS: Sixty patients after surgical treatment of oral and maxillofacial tumors with tracheostomy tube were randomly divided into DEXⅠ(D1) group, DEXⅡ(D2) group or saline (C) group with 20 patients in each group. DEXⅠ(D1) group was given a loading dose of intravenous infusion of dexmedetomidine at 0.5 μg/kg, 10 min, and then maintained with 0.2 μg/(kg·h); DEXⅡ(D2) group received a loading dose of intravenous infusion of dexmedetomidine at 0.5μg/kg, 10 min, and then maintained with 0.4 μg/(kg·h); saline (C) group received the same dose of 0.9% sodium chloride. Ramsay score, pain conditions, heart rate, blood pressure, respiratory and other changes  were compared among 3 group before administration(T0), 10 minutes after administration(T1),6 hours after administration(T2),12 hours after administration(T3) and 24 hours after administration(T4). The data was processed with SPSS 11.0 software package. RESULTS: There was no significant difference for ETCO2 among the three groups at all time points(P>0.05). At T2-T4,Ramsay score of DEXⅠ(D1) group and DEXⅡ(D2) group was significantly higher than saline (C) group(P<0.05). Ramsay score of DEXⅡ(D2) group was significantly higher than DEXⅠ(D1) group (P<0.05). At T4, VAS score of DEXⅠ(D1) group and DEXⅡ(D2) group was significantly higher than saline (C) group(P<0.05). VAS score of DEXⅡ(D2) group was significantly higher than DEXⅠ(D1) group (P<0.05). CONCLUSION: Dexmedetomidine used in postoperative oral and maxillofacial tumor patients with tracheostomy tube is safe and effective for sedation and analgesia without significant adverse reactions. Its recommended dose is a loading dose of intravenous infusion of dexmedetomidine at 0.5 μg/kg, 10 min, and then maintained with 0.4 μg/(kg·h).
[Key words]   Oral and maxillofacial tumor; Sedation; Analgesic; Dexmedetomidine

Previous:Long term observation of using fibrin glue combined with pingyangmycin for embol
Next:Extraosseous calcifying epithelial odontogenic tumor